Compare Fortinet Inc (FTNT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Fortinet Inc trades at $183.21 (market cap $139.96B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Fortinet Inc is far larger — about 28.7× Travere Therapeutics Inc. Common Stock's market cap, and Fortinet Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FTNT | TVTX | |
|---|---|---|
Market Cap | $139.96B | $4.88B |
Volume | 2,774,680 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $194.75 | $67.52 |
52-Week Low | $75.23 | $26.79 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $136.39B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $184.05, down 4.61% today, but maintains a bullish technical trend with strong fundamental performance. The company reported revenue of $6.80B in 2025 with a net income margin of 28.17%, and has consistently beaten earnings expectations in recent quarters. Recent news highlights its leadership in AI-driven cybersecurity and robust platform demand, with the stock nearing its 52-week high.
The outlook remains positive given strong earnings beats and raised 2026 guidance, though high valuation ratios (P/E 67.41) and competitive pressures pose risks. Analyst consensus is mixed with 42% buy ratings, but a $160.24 price target suggests caution relative to the current price. Institutional interest is growing, supporting momentum.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
